|
1
|
Apixaban versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
23.50
|
|
2
|
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.
|
Circulation
|
2006
|
11.78
|
|
3
|
Strategies for multivessel revascularization in patients with diabetes.
|
N Engl J Med
|
2012
|
10.79
|
|
4
|
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
|
N Engl J Med
|
2004
|
9.67
|
|
5
|
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
|
Eur Heart J
|
2013
|
9.54
|
|
6
|
Bivalirudin during primary PCI in acute myocardial infarction.
|
N Engl J Med
|
2008
|
5.86
|
|
7
|
A sensitive cardiac troponin T assay in stable coronary artery disease.
|
N Engl J Med
|
2009
|
5.81
|
|
8
|
Obstructive sleep apnea: implications for cardiac and vascular disease.
|
JAMA
|
2003
|
5.39
|
|
9
|
Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.
|
Circulation
|
2007
|
5.20
|
|
10
|
Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden.
|
Am J Cardiol
|
2002
|
4.56
|
|
11
|
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents.
|
J Am Coll Cardiol
|
2012
|
4.45
|
|
12
|
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
|
J Clin Oncol
|
2008
|
4.24
|
|
13
|
Clinical features, management, and prognosis of spontaneous coronary artery dissection.
|
Circulation
|
2012
|
4.13
|
|
14
|
The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.
|
J Am Coll Cardiol
|
2004
|
3.61
|
|
15
|
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
|
J Am Coll Cardiol
|
2011
|
3.57
|
|
16
|
Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study.
|
Circulation
|
2007
|
3.57
|
|
17
|
Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
|
J Am Coll Cardiol
|
2004
|
3.47
|
|
18
|
Natural history of asymptomatic mitral valve prolapse in the community.
|
Circulation
|
2002
|
3.40
|
|
19
|
Controversies in ventricular remodelling.
|
Lancet
|
2006
|
3.39
|
|
20
|
Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography.
|
J Am Coll Cardiol
|
2003
|
3.20
|
|
21
|
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study.
|
Ann Intern Med
|
2002
|
3.17
|
|
22
|
Familial atrial fibrillation is a genetically heterogeneous disorder.
|
J Am Coll Cardiol
|
2003
|
3.09
|
|
23
|
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
|
Lancet
|
2011
|
3.00
|
|
24
|
Obstructive sleep apnea and the recurrence of atrial fibrillation.
|
Circulation
|
2003
|
2.99
|
|
25
|
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2011
|
2.90
|
|
26
|
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.90
|
|
27
|
Controversies in stable coronary artery disease.
|
Lancet
|
2006
|
2.88
|
|
28
|
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
|
Lancet
|
2009
|
2.82
|
|
29
|
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
|
J Am Coll Cardiol
|
2008
|
2.74
|
|
30
|
Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin.
|
Mol Genet Metab
|
2005
|
2.72
|
|
31
|
Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation.
|
N Engl J Med
|
2003
|
2.68
|
|
32
|
Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
|
Circulation
|
2010
|
2.64
|
|
33
|
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
|
Circulation
|
2007
|
2.64
|
|
34
|
Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter?
|
J Am Coll Cardiol
|
2006
|
2.55
|
|
35
|
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
Circulation
|
2011
|
2.53
|
|
36
|
Trends in cause of death after percutaneous coronary intervention.
|
Circulation
|
2014
|
2.52
|
|
37
|
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women.
|
J Am Coll Cardiol
|
2002
|
2.50
|
|
38
|
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
|
J Am Coll Cardiol
|
2011
|
2.49
|
|
39
|
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol.
|
Circulation
|
2007
|
2.47
|
|
40
|
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.
|
J Am Coll Cardiol
|
2005
|
2.43
|
|
41
|
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
|
Circulation
|
2008
|
2.42
|
|
42
|
Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study.
|
J Am Coll Cardiol
|
2007
|
2.32
|
|
43
|
Syncope while driving: clinical characteristics, causes, and prognosis.
|
Circulation
|
2009
|
2.30
|
|
44
|
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
|
Circulation
|
2004
|
2.26
|
|
45
|
Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
|
Circulation
|
2012
|
2.26
|
|
46
|
Aborted myocardial infarction: a new target for reperfusion therapy.
|
Eur Heart J
|
2006
|
2.26
|
|
47
|
Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
2.25
|
|
48
|
Sudden death after myocardial infarction.
|
JAMA
|
2008
|
2.24
|
|
49
|
Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
|
Circulation
|
2007
|
2.20
|
|
50
|
The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades.
|
J Am Coll Cardiol
|
2003
|
2.19
|
|
51
|
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2010
|
2.15
|
|
52
|
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents.
|
Mayo Clin Proc
|
2004
|
2.11
|
|
53
|
Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years.
|
Mayo Clin Proc
|
2002
|
2.08
|
|
54
|
Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy.
|
Circulation
|
2002
|
2.07
|
|
55
|
Early and late effects of clopidogrel in patients with acute coronary syndromes.
|
Circulation
|
2003
|
2.05
|
|
56
|
Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management.
|
Circulation
|
2004
|
2.04
|
|
57
|
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications.
|
Eur Heart J
|
2008
|
2.03
|
|
58
|
Incidence of heart failure after myocardial infarction: is it changing over time?
|
Am J Epidemiol
|
2003
|
2.03
|
|
59
|
Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective.
|
J Am Coll Cardiol
|
2002
|
2.02
|
|
60
|
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
|
Circulation
|
2006
|
2.01
|
|
61
|
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades.
|
Eur Heart J
|
2006
|
1.97
|
|
62
|
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
|
Eur Heart J
|
2007
|
1.92
|
|
63
|
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.
|
J Am Coll Cardiol
|
2007
|
1.91
|
|
64
|
Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study.
|
J Am Coll Cardiol
|
2006
|
1.88
|
|
65
|
Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
|
Circ Heart Fail
|
2009
|
1.87
|
|
66
|
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.86
|
|
67
|
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.84
|
|
68
|
Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function.
|
Am J Cardiol
|
2005
|
1.84
|
|
69
|
Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.
|
J Am Coll Cardiol
|
2004
|
1.83
|
|
70
|
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
|
Lancet
|
2012
|
1.83
|
|
71
|
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
|
Am Heart J
|
2010
|
1.82
|
|
72
|
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience.
|
J Am Coll Cardiol
|
2008
|
1.78
|
|
73
|
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
|
Circulation
|
2012
|
1.77
|
|
74
|
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
|
Circulation
|
2007
|
1.76
|
|
75
|
Heart failure after myocardial infarction: a review.
|
Am J Med
|
2002
|
1.76
|
|
76
|
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF.
|
Am Heart J
|
2011
|
1.72
|
|
77
|
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
|
N Engl J Med
|
2009
|
1.72
|
|
78
|
Factors associated with 30-day readmission rates after percutaneous coronary intervention.
|
Arch Intern Med
|
2011
|
1.70
|
|
79
|
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
J Thorac Cardiovasc Surg
|
2011
|
1.70
|
|
80
|
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience.
|
Heart Rhythm
|
2004
|
1.70
|
|
81
|
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2009
|
1.70
|
|
82
|
The natural history of lone atrial flutter.
|
Ann Intern Med
|
2004
|
1.68
|
|
83
|
Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation.
|
Mayo Clin Proc
|
2004
|
1.65
|
|
84
|
Sarcomeric genotyping in hypertrophic cardiomyopathy.
|
Mayo Clin Proc
|
2005
|
1.65
|
|
85
|
Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy.
|
Circulation
|
2003
|
1.62
|
|
86
|
Myocardial bridging in adult patients with hypertrophic cardiomyopathy.
|
J Am Coll Cardiol
|
2003
|
1.62
|
|
87
|
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
J Thorac Cardiovasc Surg
|
2011
|
1.59
|
|
88
|
Factors associated with longer time from symptom onset to hospital presentation for patients with ST-elevation myocardial infarction.
|
Arch Intern Med
|
2008
|
1.59
|
|
89
|
Mayo Clinic Risk Score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery.
|
Circulation
|
2008
|
1.56
|
|
90
|
Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
|
Eur Heart J
|
2007
|
1.53
|
|
91
|
Sudden cardiac death: epidemiology and risk factors.
|
Nat Rev Cardiol
|
2010
|
1.53
|
|
92
|
How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy.
|
Circ Cardiovasc Genet
|
2009
|
1.53
|
|
93
|
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
|
J Am Coll Cardiol
|
2005
|
1.52
|
|
94
|
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
|
Eur Heart J
|
2008
|
1.52
|
|
95
|
Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.
|
Am J Cardiol
|
2010
|
1.52
|
|
96
|
The case for surgery in obstructive hypertrophic cardiomyopathy.
|
J Am Coll Cardiol
|
2004
|
1.52
|
|
97
|
Relation of arterial stiffness to left ventricular diastolic function and cardiovascular risk prediction in patients > or =65 years of age.
|
Am J Cardiol
|
2006
|
1.51
|
|
98
|
Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
|
Circulation
|
2004
|
1.51
|
|
99
|
Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction.
|
Am Heart J
|
2003
|
1.47
|
|
100
|
Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents.
|
JACC Cardiovasc Interv
|
2010
|
1.47
|
|
101
|
Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute.
|
Circulation
|
2004
|
1.47
|
|
102
|
CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent.
|
Am Heart J
|
2011
|
1.47
|
|
103
|
Left atrial reservoir function as a potent marker for first atrial fibrillation or flutter in persons > or = 65 years of age.
|
Am J Cardiol
|
2008
|
1.47
|
|
104
|
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.
|
J Am Soc Hypertens
|
2015
|
1.45
|
|
105
|
Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy.
|
J Cardiovasc Electrophysiol
|
2007
|
1.44
|
|
106
|
Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met?
|
Am Heart J
|
2006
|
1.44
|
|
107
|
Revascularization in severe left ventricular dysfunction: the role of viability testing.
|
J Am Coll Cardiol
|
2005
|
1.42
|
|
108
|
Socioeconomic status and outcome following acute myocardial infarction in elderly patients.
|
Arch Intern Med
|
2004
|
1.42
|
|
109
|
Relapse and mortality following cardioversion of new-onset vs. recurrent atrial fibrillation and atrial flutter in the elderly.
|
Eur Heart J
|
2006
|
1.42
|
|
110
|
Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience.
|
Nat Clin Pract Cardiovasc Med
|
2007
|
1.41
|
|
111
|
Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions.
|
Am Heart J
|
2003
|
1.41
|
|
112
|
Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations.
|
Circulation
|
2003
|
1.41
|
|
113
|
Atrial fibrillation in myocardial infarction patients: Impact on health care utilization.
|
Am Heart J
|
2013
|
1.40
|
|
114
|
Effect of radiofrequency ablation of atrial flutter on the natural history of subsequent atrial arrhythmias.
|
J Cardiovasc Electrophysiol
|
2008
|
1.40
|
|
115
|
Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability.
|
Mayo Clin Proc
|
2004
|
1.40
|
|
116
|
Implantable cardioverter defibrillators in patients with valvular cardiomyopathy.
|
J Cardiovasc Electrophysiol
|
2012
|
1.39
|
|
117
|
Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial.
|
Eur Heart J
|
2013
|
1.38
|
|
118
|
Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
|
Am J Cardiol
|
2006
|
1.37
|
|
119
|
P wave signal-averaged electrocardiography to identify risk for atrial fibrillation.
|
Pacing Clin Electrophysiol
|
2002
|
1.37
|
|
120
|
Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction.
|
Am Heart J
|
2006
|
1.36
|
|
121
|
Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle.
|
Circulation
|
2004
|
1.34
|
|
122
|
Yield of genetic testing in hypertrophic cardiomyopathy.
|
Mayo Clin Proc
|
2005
|
1.31
|
|
123
|
Hypertension: a global perspective.
|
Circulation
|
2011
|
1.31
|
|
124
|
Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years.
|
Eur Heart J
|
2008
|
1.30
|
|
125
|
When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials.
|
J Am Coll Cardiol
|
2010
|
1.28
|
|
126
|
Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease.
|
Circulation
|
2003
|
1.27
|
|
127
|
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
|
J Am Coll Cardiol
|
2011
|
1.27
|
|
128
|
Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations.
|
Mayo Clin Proc
|
2006
|
1.26
|
|
129
|
2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient management.
|
Heart
|
2013
|
1.25
|
|
130
|
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.
|
Circulation
|
2007
|
1.24
|
|
131
|
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.
|
Eur Heart J
|
2005
|
1.24
|
|
132
|
Risks for atrial fibrillation and congestive heart failure in patients >/=65 years of age with abnormal left ventricular diastolic relaxation.
|
Am J Cardiol
|
2004
|
1.19
|
|
133
|
Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?
|
Lancet
|
2013
|
1.18
|
|
134
|
Coronary ischemic events after first atrial fibrillation: risk and survival.
|
Am J Med
|
2007
|
1.17
|
|
135
|
Changing trends of hospital utilization in patients after their first episode of atrial fibrillation.
|
Am J Cardiol
|
2008
|
1.17
|
|
136
|
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.17
|
|
137
|
Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both?
|
Eur Heart J
|
2007
|
1.17
|
|
138
|
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
|
J Clin Oncol
|
2004
|
1.16
|
|
139
|
Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study.
|
Stroke
|
2005
|
1.15
|
|
140
|
Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.
|
J Am Coll Cardiol
|
2015
|
1.15
|
|
141
|
Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort.
|
Eur Heart J
|
2007
|
1.10
|
|
142
|
Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary intervention: a single-institution experience.
|
Circulation
|
2007
|
1.10
|
|
143
|
Five-year follow-up of a randomized comparison between off-pump and on-pump stable multivessel coronary artery bypass grafting. The MASS III Trial.
|
Circulation
|
2010
|
1.10
|
|
144
|
Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries.
|
Circulation
|
2010
|
1.08
|
|
145
|
Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators.
|
Circulation
|
2007
|
1.07
|
|
146
|
Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy.
|
Eur Heart J
|
2005
|
1.06
|
|
147
|
Defining gene transfer before expecting gene therapy: putting the horse before the cart.
|
Circulation
|
2002
|
1.05
|
|
148
|
Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.
|
Am Heart J
|
2004
|
1.05
|
|
149
|
Epidemiological profile of atrial fibrillation: a contemporary perspective.
|
Prog Cardiovasc Dis
|
2005
|
1.04
|
|
150
|
Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction.
|
Congest Heart Fail
|
2007
|
1.04
|
|
151
|
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
|
Circ Heart Fail
|
2009
|
1.04
|
|
152
|
One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials.
|
J Thorac Cardiovasc Surg
|
2005
|
1.04
|
|
153
|
Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
|
Circulation
|
2012
|
1.04
|
|
154
|
Delay in presentation and reperfusion therapy in ST-elevation myocardial infarction.
|
Am J Med
|
2008
|
1.04
|
|
155
|
Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease.
|
Ann Thorac Surg
|
2007
|
1.02
|
|
156
|
A total of 1,007 percutaneous coronary interventions without onsite cardiac surgery: acute and long-term outcomes.
|
J Am Coll Cardiol
|
2006
|
1.01
|
|
157
|
Effects of quinapril on left atrial structural remodeling and arterial stiffness.
|
Am J Cardiol
|
2006
|
1.01
|
|
158
|
Echocardiographic-determined septal morphology in Z-disc hypertrophic cardiomyopathy.
|
Biochem Biophys Res Commun
|
2006
|
1.00
|
|
159
|
Chronic coronary artery disease: diagnosis and management.
|
Mayo Clin Proc
|
2009
|
1.00
|
|
160
|
Management of stable coronary artery disease.
|
Lancet
|
2010
|
1.00
|
|
161
|
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
|
Mayo Clin Proc
|
2011
|
1.00
|
|
162
|
Outcomes of clinically significant idiopathic pericardial effusion requiring intervention.
|
Am J Cardiol
|
2003
|
0.99
|
|
163
|
Atrial fibrillation: an old disease, a new epidemic.
|
Am J Med
|
2002
|
0.99
|
|
164
|
Current and future treatment strategies for refractory angina.
|
Mayo Clin Proc
|
2004
|
0.99
|
|
165
|
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
|
Circulation
|
2013
|
0.99
|
|
166
|
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.97
|
|
167
|
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
|
PLoS One
|
2013
|
0.97
|
|
168
|
Long-term risk of atrial fibrillation with symptomatic gastroesophageal reflux disease and esophagitis.
|
Am J Cardiol
|
2008
|
0.97
|
|
169
|
Atrial fibrillation: a perspective: thinking inside and outside the box.
|
Circulation
|
2004
|
0.97
|
|
170
|
Usefulness of QRS duration in the absence of bundle branch block as an early predictor of survival in non-ST elevation acute myocardial infarction.
|
Am J Cardiol
|
2002
|
0.96
|
|
171
|
Renal function and mortality following cardiac resynchronization therapy.
|
Eur Heart J
|
2010
|
0.96
|
|
172
|
Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial.
|
Circulation
|
2004
|
0.96
|
|
173
|
Effect of atrial fibrillation pattern on survival in a community-based cohort.
|
Am J Cardiol
|
2005
|
0.95
|
|
174
|
Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy.
|
Am J Cardiol
|
2010
|
0.95
|
|
175
|
Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy.
|
Am Heart J
|
2008
|
0.94
|
|
176
|
Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
|
Circ Heart Fail
|
2013
|
0.94
|
|
177
|
Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies.
|
Am Heart J
|
2008
|
0.92
|
|
178
|
Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.91
|
|
179
|
Ventricular arrhythmias after acute myocardial infarction: a 20-year community study.
|
Am Heart J
|
2006
|
0.91
|
|
180
|
Catheter ablation for atrial fibrillation in patients with obesity.
|
Circulation
|
2008
|
0.91
|
|
181
|
Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.
|
EuroIntervention
|
2009
|
0.91
|
|
182
|
Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications.
|
Circ Cardiovasc Interv
|
2013
|
0.91
|
|
183
|
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2005
|
0.91
|
|
184
|
Percutaneous coronary intervention for chronic stable angina: a reassessment.
|
JACC Cardiovasc Interv
|
2008
|
0.90
|
|
185
|
Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction.
|
Am Heart J
|
2007
|
0.90
|
|
186
|
Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation.
|
Am J Hematol
|
2009
|
0.90
|
|
187
|
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death.
|
Am Heart J
|
2007
|
0.90
|
|
188
|
Utility of left bundle branch block as a diagnostic criterion for acute myocardial infarction.
|
Am J Cardiol
|
2011
|
0.90
|
|
189
|
Changing late prognosis of acute myocardial infarction: impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator.
|
Circulation
|
2003
|
0.90
|
|
190
|
Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction.
|
Catheter Cardiovasc Interv
|
2013
|
0.90
|
|
191
|
Bronchogenic cyst causing atrial fibrillation by impinging the right inferior pulmonary vein.
|
Am J Med Sci
|
2006
|
0.90
|
|
192
|
From randomized trials to registry studies: translating data into clinical information.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.90
|
|
193
|
Functional and prognostic significance of exercise-induced ventricular arrhythmias in patients with suspected coronary artery disease.
|
Am J Cardiol
|
2002
|
0.89
|
|
194
|
Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.
|
Am J Cardiol
|
2007
|
0.89
|
|
195
|
Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
|
J Am Coll Cardiol
|
2005
|
0.89
|
|
196
|
Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction.
|
Am J Cardiol
|
2010
|
0.89
|
|
197
|
Long-term subjective memory function in ventricular fibrillation out-of-hospital cardiac arrest survivors resuscitated by early defibrillation.
|
Resuscitation
|
2004
|
0.88
|
|
198
|
Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
|
Am Heart J
|
2004
|
0.88
|
|
199
|
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.
|
Am Heart J
|
2006
|
0.87
|
|
200
|
Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.
|
Hypertension
|
2015
|
0.87
|
|
201
|
Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics.
|
Eur Heart J
|
2012
|
0.87
|
|
202
|
Expression patterns of cardiac myofilament proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic cardiomyopathy.
|
Circ Heart Fail
|
2009
|
0.86
|
|
203
|
Systems of care to improve timeliness of reperfusion therapy for ST-segment elevation myocardial infarction during off hours: the Mayo Clinic STEMI protocol.
|
JACC Cardiovasc Interv
|
2008
|
0.86
|
|
204
|
Procedural factors associated with percutaneous coronary intervention-related ischemic stroke.
|
JACC Cardiovasc Interv
|
2012
|
0.86
|
|
205
|
Controversies in the cardiovascular management of type 2 diabetes.
|
Heart
|
2010
|
0.86
|
|
206
|
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation.
|
Am J Med
|
2013
|
0.86
|
|
207
|
Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease.
|
Circ Cardiovasc Interv
|
2012
|
0.86
|
|
208
|
Methods of coronary revascularization--things may not be as they seem.
|
N Engl J Med
|
2005
|
0.85
|
|
209
|
Prevalence and clinical outcomes of patients with multiple potential causes of syncope.
|
Mayo Clin Proc
|
2003
|
0.85
|
|
210
|
Predictors of unsuccessful electrical cardioversion in atrial fibrillation.
|
Am J Cardiol
|
2002
|
0.85
|
|
211
|
Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
|
Am Heart J
|
2005
|
0.85
|
|
212
|
Trends, predictors, and outcomes of cerebrovascular events related to percutaneous coronary intervention: a 16-year single-center experience.
|
JACC Cardiovasc Interv
|
2011
|
0.85
|
|
213
|
Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation.
|
Am Heart J
|
2002
|
0.85
|
|
214
|
Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society.
|
Circulation
|
2005
|
0.85
|
|
215
|
Sex differences in evaluation and outcome after stress testing.
|
Mayo Clin Proc
|
2002
|
0.85
|
|
216
|
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.
|
Coron Artery Dis
|
2007
|
0.84
|
|
217
|
Diastolic dysfunction in patients undergoing cardiac surgery: a pathophysiological mechanism underlying the initiation of new-onset post-operative atrial fibrillation.
|
J Am Coll Cardiol
|
2011
|
0.84
|
|
218
|
Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation.
|
J Am Coll Cardiol
|
2002
|
0.84
|
|
219
|
Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal.
|
J Am Coll Cardiol
|
2002
|
0.84
|
|
220
|
Age- and sex-related atrial electrophysiologic and structural changes.
|
Am J Cardiol
|
2004
|
0.84
|
|
221
|
Prevalence, hemodynamics, and cytokine profile of effusive-constrictive pericarditis in patients with tuberculous pericardial effusion.
|
PLoS One
|
2013
|
0.84
|
|
222
|
Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction.
|
Am J Cardiol
|
2003
|
0.83
|
|
223
|
Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial.
|
Circulation
|
2012
|
0.83
|
|
224
|
Aspirin beyond platelet inhibition.
|
Am J Cardiol
|
2002
|
0.83
|
|
225
|
The SYNTAX trial: a perspective.
|
Circ Cardiovasc Interv
|
2009
|
0.83
|
|
226
|
Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations.
|
Am Heart J
|
2009
|
0.83
|
|
227
|
Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.
|
Circulation
|
2015
|
0.83
|
|
228
|
Deformation patterns in genotyped patients with hypertrophic cardiomyopathy.
|
Eur Heart J Cardiovasc Imaging
|
2013
|
0.83
|
|
229
|
Long-term efficacy of transcatheter closure of ventricular septal defect in combination with percutaneous coronary intervention in patients with ventricular septal defect complicating acute myocardial infarction: a multicentre study.
|
EuroIntervention
|
2013
|
0.82
|
|
230
|
The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion.
|
Am Heart J
|
2006
|
0.82
|
|
231
|
Stem cells: clinical trials results the end of the beginning or the beginning of the end?
|
Cardiovasc Hematol Disord Drug Targets
|
2010
|
0.82
|
|
232
|
Clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy with latent obstruction.
|
Am Heart J
|
2008
|
0.82
|
|
233
|
Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram.
|
J Am Coll Cardiol
|
2009
|
0.82
|
|
234
|
Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study.
|
J Am Coll Cardiol
|
2009
|
0.82
|
|
235
|
The prognostic significance of exercise-induced atrial arrhythmias.
|
J Am Coll Cardiol
|
2004
|
0.81
|
|
236
|
Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study.
|
Circulation
|
2003
|
0.81
|
|
237
|
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005.
|
Am Heart J
|
2008
|
0.81
|
|
238
|
Modern management of acute myocardial infarction.
|
Curr Probl Cardiol
|
2012
|
0.81
|
|
239
|
Atrial fibrillation after surgical correction of mitral regurgitation in sinus rhythm: incidence, outcome, and determinants.
|
Circulation
|
2004
|
0.81
|
|
240
|
Effects of surgical septal myectomy on left ventricular wall thickness and diastolic filling.
|
Am J Cardiol
|
2007
|
0.81
|
|
241
|
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.
|
J Am Heart Assoc
|
2013
|
0.81
|
|
242
|
A randomized comparative study of patients undergoing myocardial revascularization with or without cardiopulmonary bypass surgery: The MASS III Trial.
|
Trials
|
2008
|
0.81
|
|
243
|
Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction.
|
Am J Cardiol
|
2008
|
0.81
|
|
244
|
Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials.
|
Eur Heart J
|
2003
|
0.81
|
|
245
|
Catheter ablation for atrial fibrillation in patients with the Marfan and Marfan-like syndromes.
|
J Interv Card Electrophysiol
|
2007
|
0.81
|
|
246
|
Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter.
|
Am Heart J
|
2005
|
0.81
|
|
247
|
And the answer is, it doesn't much matter.
|
Circulation
|
2002
|
0.80
|
|
248
|
Cell therapy for cardiovascular disease: what cells, what diseases and for whom?
|
Nat Clin Pract Cardiovasc Med
|
2005
|
0.80
|
|
249
|
Outcome of patients with newly diagnosed atrial fibrillation at the Mayo Clinic and residing in that area.
|
Am J Cardiol
|
2004
|
0.80
|
|
250
|
Is viability imaging still relevant in 2012?
|
JACC Cardiovasc Imaging
|
2012
|
0.80
|
|
251
|
Happy birthday European Heart Journal: in 30 years, from Cinderella to centre stage.
|
Eur Heart J
|
2010
|
0.80
|
|
252
|
Outcomes and in-hospital treatment of out-of-hospital cardiac arrest patients resuscitated from ventricular fibrillation by early defibrillation.
|
Mayo Clin Proc
|
2004
|
0.80
|
|
253
|
Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial).
|
Am J Cardiol
|
2008
|
0.80
|
|
254
|
The management of combined coronary artery disease and peripheral vascular disease.
|
Eur Heart J
|
2010
|
0.80
|
|
255
|
Cancer-related deaths among different treatment options in chronic coronary artery disease: results of a 6-year follow-up of the MASS II study.
|
Coron Artery Dis
|
2012
|
0.80
|
|
256
|
Prediction of short- and long-term outcomes by electrocardiography in survivors of out-of-hospital cardiac arrest.
|
Resuscitation
|
2004
|
0.80
|
|
257
|
Addendum to "Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology". Public safety issues in patients with implantable defibrillators. A Scientific statement from the American Heart Association and the Heart Rhythm Society.
|
Heart Rhythm
|
2007
|
0.80
|
|
258
|
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy.
|
Am Heart J
|
2007
|
0.80
|
|
259
|
Viral infection, inflammation, and the risk of idiopathic dilated cardiomyopathy: can the fire be extinguished?
|
Am J Cardiol
|
2002
|
0.79
|
|
260
|
Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks.
|
Am Heart J
|
2012
|
0.79
|
|
261
|
Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients.
|
Mayo Clin Proc
|
2013
|
0.79
|
|
262
|
Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial.
|
J Am Coll Cardiol
|
2006
|
0.79
|
|
263
|
Effect of septal ablation on myocardial relaxation and left atrial pressure in hypertrophic cardiomyopathy an invasive hemodynamic study.
|
JACC Cardiovasc Interv
|
2008
|
0.79
|
|
264
|
Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation.
|
Stroke
|
2013
|
0.79
|
|
265
|
Hypotheses, rationale, design, and methods for prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifest myocardial infarction. A comparative analysis of biomarkers and cardiac magnetic resonance. The MASS-V Trial.
|
BMC Cardiovasc Disord
|
2012
|
0.79
|
|
266
|
Modern management of acute myocardial infarction.
|
Curr Probl Cardiol
|
2006
|
0.79
|
|
267
|
C-reactive protein, left atrial volume, and atrial fibrillation: a prospective study in high-risk elderly.
|
Echocardiography
|
2009
|
0.79
|
|
268
|
New insights into the predictors of left atrial stunning after successful direct-current cardioversion of atrial fibrillation and flutter.
|
J Am Soc Echocardiogr
|
2008
|
0.78
|
|
269
|
Role of smoking in the recurrence of atrial arrhythmias after cardioversion.
|
Am J Cardiol
|
2009
|
0.78
|
|
270
|
Making sense of the maze: which patients with atrial fibrillation will benefit?
|
JAMA
|
2005
|
0.78
|
|
271
|
Comparison of frequency of recurrent syncope after beta-blocker therapy versus conservative management for patients with vasovagal syncope.
|
Am J Cardiol
|
2003
|
0.78
|
|
272
|
Role of cardiac MRI and nuclear imaging in cardiac resynchronization therapy.
|
Nat Rev Cardiol
|
2009
|
0.78
|
|
273
|
Beneficial effect of reperfusion therapy beyond the preservation of left ventricular function in patients with acute ST-segment elevation myocardial infarction.
|
Int J Cardiol
|
2009
|
0.78
|
|
274
|
Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking.
|
Am J Cardiol
|
2004
|
0.78
|
|
275
|
Sudden cardiac death risk in hypertrophic cardiomyopathy.
|
Eur Heart J
|
2009
|
0.77
|
|
276
|
Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial.
|
EuroIntervention
|
2016
|
0.77
|
|
277
|
Stem cells to repair the heart: a clinical perspective.
|
Circ Res
|
2003
|
0.77
|
|
278
|
Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls.
|
Eur Heart J
|
2007
|
0.77
|
|
279
|
Images in cardiovascular medicine. Severe left atrial appendage stunning after electrical cardioversion of atrial fibrillation.
|
Circulation
|
2008
|
0.77
|
|
280
|
Impact of prehospital electrocardiogram protocol and immediate catheterization team activation for patients with ST-elevation-myocardial infarction.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.77
|
|
281
|
Modern management of acute myocardial infarction.
|
Curr Probl Cardiol
|
2003
|
0.77
|
|
282
|
Addendum to "Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society.
|
Circulation
|
2007
|
0.77
|
|
283
|
Ventricular tachycardia in hypertrophic cardiomyopathy with apical aneurysm.
|
Ann Thorac Surg
|
2011
|
0.77
|
|
284
|
Prospective, randomized comparison of two biphasic waveforms for the efficacy and safety of transthoracic biphasic cardioversion of atrial fibrillation.
|
Heart Rhythm
|
2005
|
0.77
|
|
285
|
The timing of reperfusion therapy.
|
Nat Clin Pract Cardiovasc Med
|
2005
|
0.77
|
|
286
|
Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy.
|
J Am Soc Echocardiogr
|
2006
|
0.76
|
|
287
|
Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy.
|
Chest
|
2015
|
0.76
|
|
288
|
Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
|
Catheter Cardiovasc Interv
|
2012
|
0.76
|
|
289
|
Score indices for predicting electrophysiologic outcomes in patients with unexplained syncope.
|
J Interv Card Electrophysiol
|
2005
|
0.76
|
|
290
|
Percutaneous coronary intervention vs thrombolysis for ST-elevation myocardial infarction.
|
JAMA
|
2007
|
0.76
|
|
291
|
Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
|
Cardiovasc Diabetol
|
2015
|
0.75
|
|
292
|
To open or not to open: that remains the question.
|
Eur Heart J
|
2004
|
0.75
|
|
293
|
Antithrombotic therapy for the prevention of reinfarction after reperfusion therapy: the price of success.
|
Rev Esp Cardiol
|
2009
|
0.75
|
|
294
|
Is there a role for pre-hospital fibrinolysis in North America?
|
JACC Cardiovasc Interv
|
2011
|
0.75
|
|
295
|
Potential relief for refractory angina.
|
N Engl J Med
|
2015
|
0.75
|
|
296
|
Symptomatic pulmonary hypertension with giant left atrial v waves after surgical maze procedures: evaluation by comprehensive hemodynamic catheterization.
|
Heart Rhythm
|
2013
|
0.75
|
|
297
|
Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy.
|
Pacing Clin Electrophysiol
|
2008
|
0.75
|
|
298
|
Facilitated angioplasty: paradise lost.
|
Lancet
|
2006
|
0.75
|
|
299
|
Optimal anticoagulation therapy in patients with valvular heart disease or atrial fibrillation.
|
Arch Intern Med
|
2009
|
0.75
|
|
300
|
Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes.
|
J Gen Intern Med
|
2010
|
0.75
|
|
301
|
Should percutaneous revascularization for stable coronary artery disease be performed sooner or later?
|
JACC Cardiovasc Interv
|
2008
|
0.75
|
|
302
|
Clinical and economic outcomes after introduction of drug-eluting stents.
|
Am J Manag Care
|
2010
|
0.75
|
|
303
|
Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial.
|
BMC Cardiovasc Disord
|
2010
|
0.75
|
|
304
|
Selection of the optimal reperfusion strategy for STEMI: does time matter?
|
Eur Heart J
|
2006
|
0.75
|
|
305
|
Outcomes of a system-wide protocol for elective and nonelective coronary angioplasty at sites without on-site surgery: the Mayo Clinic experience.
|
Mayo Clin Proc
|
2009
|
0.75
|
|
306
|
Reperfusion strategies. Comparison of facilitated versus primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction.
|
Rev Cardiovasc Med
|
2006
|
0.75
|
|
307
|
Pharmacological facilitation of coronary intervention in ST-segment elevation myocardial infarction: time is of the essence.
|
JACC Cardiovasc Interv
|
2010
|
0.75
|
|
308
|
Markers of inflammation and thrombosis: clues to plaque instability?
|
Am Heart J
|
2003
|
0.75
|
|
309
|
New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy.
|
Circulation
|
2009
|
0.75
|
|
310
|
Is incomplete revascularization during PCI and stenting associated with adverse long-term outcomes?
|
Nat Clin Pract Cardiovasc Med
|
2006
|
0.75
|
|
311
|
Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
312
|
Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope.
|
Am J Cardiol
|
2012
|
0.75
|
|
313
|
Reply: NOAC Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
314
|
Cardiomyopathy induced by pulmonary vein tachycardia cured by catheter ablation.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.75
|
|
315
|
Critical appraisal of transesophageal echocardiography in cardioversion of atrial fibrillation.
|
Am J Med
|
2002
|
0.75
|
|
316
|
Ambulatory monitoring of aborted sudden cardiac death related to hypertrophic cardiomyopathy.
|
Nat Clin Pract Cardiovasc Med
|
2005
|
0.75
|
|
317
|
Erratum.
|
Eur Heart J Qual Care Clin Outcomes
|
2017
|
0.75
|
|
318
|
Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction.
|
Ann Intern Med
|
2005
|
0.75
|
|
319
|
Noninvasive assessment of acute changes in atrial electrophysiology after cardioversion by signal-averaged P-wave electrocardiography.
|
Pacing Clin Electrophysiol
|
2005
|
0.75
|
|
320
|
AHA/ACC/ESC 2006 atrial fibrillation guidelines: looking towards the future.
|
Nat Clin Pract Cardiovasc Med
|
2007
|
0.75
|
|
321
|
Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department.
|
Acad Emerg Med
|
2009
|
0.75
|
|
322
|
Diagnostic Performance of Myocardial CT Perfusion Imaging With or Without Coronary CT Angiography.
|
JACC Cardiovasc Imaging
|
2015
|
0.75
|
|
323
|
State of the art: optimal medical therapy - competing with or complementary to revascularisation in patients with coronary artery disease?
|
EuroIntervention
|
2017
|
0.75
|
|
324
|
Current concepts and management of atrial fibrillation: the American perspective.
|
Chin Med J (Engl)
|
2013
|
0.75
|
|
325
|
Integrated management of patients with diabetes mellitus and ischemic heart disease: PCI, CABG, and medical therapy.
|
Curr Probl Cardiol
|
2005
|
0.75
|
|
326
|
Thrombolysis in acute myocardial infarction: current status.
|
Med Clin North Am
|
2007
|
0.75
|
|
327
|
Anticoagulation for prosthetic heart valves: unresolved questions requiring answers.
|
Curr Opin Cardiol
|
2016
|
0.75
|
|
328
|
Dabigatran Versus Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
329
|
Outcome of septal myectomy in patients with Fabry's disease.
|
Ann Thorac Surg
|
2012
|
0.75
|
|
330
|
Predicting and preventing heart failure rehospitalizations: is there a role for implantable device diagnostics?
|
Am J Cardiol
|
2012
|
0.75
|
|
331
|
[Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments].
|
Rev Esp Cardiol
|
2011
|
0.75
|
|
332
|
Ethical issues in cardiovascular research involving humans.
|
Circulation
|
2009
|
0.75
|
|
333
|
Current indications for percutaneous coronary intervention for chronic stable angina: implications of the COURAGE Trial.
|
Rev Cardiovasc Med
|
2007
|
0.75
|